Pulmatrix Investor Relations Material
Latest events
M&A Announcement
Pulmatrix
Q1 2025
25 Jul, 2025
Q4 2024
21 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pulmatrix Inc
Access all reports
Pulmatrix Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases. The company utilizes its proprietary iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) technology to formulate dry powder drugs for efficient delivery to the lungs. Pulmatrix's pipeline includes treatments for conditions such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and other respiratory disorders. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Pulmatrix Inc
M&A Announcement
Pulmatrix Inc
M&A Announcement
Pulmatrix Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PULM
Country
🇺🇸 United States